• Home
  1. Home
  2. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
Scientific article
OA Policy
English

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

ContributorsStrand, Vibeke; Michalska, Margaret; Birchwood, Christine; Pei, Jinglan; Tuckwell, Katie; Finch, Rebecca; Gabay, Cem; Kavanaugh, Arthur; Jones, Graeme
Published inRMD Open, vol. 3, no. 2, e000496
Publication date2017
Abstract

Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This study compared the benefit of TCZ versus MTX or ADA monotherapy for improving patient-reported outcomes (PROs) in patients with RA.

Affiliation entities
Research groups
Citation (ISO format)
STRAND, Vibeke et al. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. In: RMD Open, 2017, vol. 3, n° 2, p. e000496. doi: 10.1136/rmdopen-2017-000496
Main files (1)
Article (Published version)
accessLevelPublic CC BY-NC
Identifiers
Journal ISSN2056-5933
393views
254downloads

Technical informations

Creation03/09/2018 11:20:00
First validation03/09/2018 11:20:00
Update24/01/2025 14:27:56
Status update24/01/2025 14:27:56
Last indexation24/01/2025 14:36:22
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack